v3.25.2
Segment Reporting - Schdule of Operating Financial Result (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Total Revenue $ 37,958   $ 3,500   $ 57,753 $ 3,500
Less: Significant and other segment expenses            
Cost of Product Sales 1,279   0   2,164 0
Research and development 62,227   48,655   123,863 105,147
Royalty interest expense 7,854   0   15,903 0
Segment net loss (71,847) $ (84,846) (68,063) $ (72,400) (156,693) (140,463)
Biopharmaceutical Cancer Therapeutics Member            
Segment Reporting Information [Line Items]            
Total Revenue 37,958   3,500   57,753 3,500
Less: Significant and other segment expenses            
Cost of Product Sales 1,279   0   2,164 0
Other R&D programs 1,826   534   2,747 1,500
Personnel cost and other expenses 18,997   14,861   35,528 29,202
Commercial related expenses 9,914   7,560   20,739 13,392
Personnel cost and other expenses 19,307   4,153   38,389 8,258
Other SG&A expenses 4,993   11,770   9,405 20,099
Stock-based compenstion 13,787   9,896   24,167 18,795
Royalty interest expense 7,854   0   15,903 0
Interest expense (income), net (5,946)   (6,239)   (13,127) (13,440)
Other expense, net 586   86   807 173
Segment net loss (71,847)   (68,063)   (156,693) (140,463)
Biopharmaceutical Cancer Therapeutics Member | Revumenib-Related Costs Member            
Less: Significant and other segment expenses            
Research and development 28,155   20,439   48,960 51,880
Biopharmaceutical Cancer Therapeutics Member | Axatilimab-Related Costs Membe            
Less: Significant and other segment expenses            
Research and development $ 9,053   $ 8,503   $ 28,764 $ 14,104